Details of the Drug

General Information of Drug (ID: DMAUHQX)

Drug Name

Methdilazine

Synonyms

Disyncram; Methdilazinum; Methodilazine; Metodilazina; Tacaryl; Tacazyl; Tacryl; Methilazine hydrochloride; Methdilazine (INN); Methdilazinum [INN-Latin]; Metodilazina [INN-Spanish]; Tacaryl (TN); Methdilazine [USAN:INN:BAN]; 10-((1-Methyl-3-pyrrolidinyl)methyl)phenothiazine; 10-((1-methyl-3-pyrrolidinyl)methyl)-10H-phenothiazine; 10-[(1-Methylpyrrolidin-3-yl)methyl]phenothiazine; 10-[(1-methylpyrrolidin-3-yl)methyl]-10H-phenothiazine

Indication

Disease Entry	ICD 11	Status	REF
Allergic rhinitis	CA08.0	Approved	[1], [2]

Therapeutic Class

Antihistamines

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 1

Molecular Weight (mw)

296.4

Topological Polar Surface Area (xlogp)

5.2

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption: The drug is well absorbed in the digestive tract [3]

Chemical Identifiers

Formula: C18H20N2S
IUPAC Name: 10-[(1-methylpyrrolidin-3-yl)methyl]phenothiazine
Canonical SMILES: CN1CCC(C1)CN2C3=CC=CC=C3SC4=CC=CC=C42
InChI: InChI=1S/C18H20N2S/c1-19-11-10-14(12-19)13-20-15-6-2-4-8-17(15)21-18-9-5-3-7-16(18)20/h2-9,14H,10-13H2,1H3
InChIKey: HTMIBDQKFHUPSX-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 14677
ChEBI ID: CHEBI:6823
CAS Number: 1982-37-2
DrugBank ID: DB00902
TTD ID: D0LR0R

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Histamine H1 receptor (H1R)	TTTIBOJ	HRH1_HUMAN	Antagonist	[4]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Allergic rhinitis

ICD Disease Classification

CA08.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Histamine H1 receptor (H1R)	DTT	HRH1	6.74E-01	0.13	0.43

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Methdilazine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Chlorpheniramine	DM5URA2	Moderate	Additive anticholinergic effects by the combination of Methdilazine and Chlorpheniramine.	Vasomotor/allergic rhinitis [CA08]	[13]
Acrivastine	DMTIGA0	Moderate	Additive anticholinergic effects by the combination of Methdilazine and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[14]
-----------

Coadministration of a Drug Treating the Disease Different from Methdilazine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Mepyramine	DMB4SFH	Moderate	Additive anticholinergic effects by the combination of Methdilazine and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[14]
Phenyltoloxamine	DMKAEQW	Moderate	Additive anticholinergic effects by the combination of Methdilazine and Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[14]
Memantine	DMD9WSC	Moderate	Additive anticholinergic effects by the combination of Methdilazine and Memantine.	Alzheimer disease [8A20]	[13]
Rivastigmine	DMG629M	Moderate	Antagonize the effect of Methdilazine when combined with Rivastigmine.	Alzheimer disease [8A20]	[15]
Amyl nitrite	DMJKO05	Moderate	Additive hypotensive effects by the combination of Methdilazine and Amyl nitrite.	Angina pectoris [BA40]	[16]
Nifedipine	DMSVOZT	Moderate	Additive hypotensive effects by the combination of Methdilazine and Nifedipine.	Angina pectoris [BA40]	[16]
Ephedrine	DMMV0KW	Moderate	Antagonize the effect of Methdilazine when combined with Ephedrine.	Asthma [CA23]	[17]
Lisdexamfetamine	DM6W8V5	Moderate	Antagonize the effect of Methdilazine when combined with Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[17]
Desipramine	DMT2FDC	Moderate	Increased plasma concentrations of Methdilazine and Desipramine due to competitive inhibition of the same metabolic pathway.	Attention deficit hyperactivity disorder [6A05]	[18]
Cariprazine	DMJYDVK	Moderate	Additive anticholinergic effects by the combination of Methdilazine and Cariprazine.	Bipolar disorder [6A60]	[13]
Acetylcholine	DMDF79Z	Moderate	Antagonize the effect of Methdilazine when combined with Acetylcholine.	Cataract [9B10]	[19]
Umeclidinium	DM4E8O9	Moderate	Additive anticholinergic effects by the combination of Methdilazine and Umeclidinium.	Chronic obstructive pulmonary disease [CA22]	[20]
Tiotropium	DMFDC0Q	Moderate	Additive anticholinergic effects by the combination of Methdilazine and Tiotropium.	Chronic obstructive pulmonary disease [CA22]	[20]
Revefenacin	DMMP5SI	Moderate	Additive anticholinergic effects by the combination of Methdilazine and Revefenacin.	Chronic obstructive pulmonary disease [CA22]	[20]
Cyclobenzaprine	DM1YBRM	Moderate	Additive anticholinergic effects by the combination of Methdilazine and Cyclobenzaprine.	Depression [6A70-6A7Z]	[13]
Selegiline	DM6034S	Moderate	Additive hypotensive effects by the combination of Methdilazine and Selegiline.	Depression [6A70-6A7Z]	[21]
Isocarboxazid	DMAF1NB	Moderate	Additive hypotensive effects by the combination of Methdilazine and Isocarboxazid.	Depression [6A70-6A7Z]	[21]
OPC-34712	DMHG57U	Moderate	Additive anticholinergic effects by the combination of Methdilazine and OPC-34712.	Depression [6A70-6A7Z]	[13]
Clomipramine	DMINRKW	Moderate	Increased plasma concentrations of Methdilazine and Clomipramine due to competitive inhibition of the same metabolic pathway.	Depression [6A70-6A7Z]	[18]
Doxepin	DMPI98T	Moderate	Increased plasma concentrations of Methdilazine and Doxepin due to competitive inhibition of the same metabolic pathway.	Depression [6A70-6A7Z]	[18]
Maprotiline	DMPWB7T	Moderate	Additive anticholinergic effects by the combination of Methdilazine and Maprotiline.	Depression [6A70-6A7Z]	[13]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Methdilazine and Esketamine.	Depression [6A70-6A7Z]	[22]
Mepenzolate	DM8YU2F	Moderate	Additive anticholinergic effects by the combination of Methdilazine and Mepenzolate.	Digestive system disease [DE2Z]	[14]
Oxybutynine	DMJPBAX	Moderate	Additive anticholinergic effects by the combination of Methdilazine and Oxybutynine.	Discovery agent [N.A.]	[13]
Tetrabenazine	DMYWQ0O	Major	Increased risk of prolong QT interval by the combination of Methdilazine and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[23]
Deutetrabenazine	DMUPFLI	Major	Increased risk of prolong QT interval by the combination of Methdilazine and Deutetrabenazine.	Dystonic disorder [8A02]	[24]
Zonisamide	DM0DTF7	Major	Additive CNS depression effects by the combination of Methdilazine and Zonisamide.	Epilepsy/seizure [8A61-8A6Z]	[25]
Diphenhydramine	DMKQTBA	Moderate	Additive anticholinergic effects by the combination of Methdilazine and Diphenhydramine.	Episodic vestibular syndrome [AB31]	[13]
Ethacrynic acid	DM60QMR	Moderate	Additive hypotensive effects by the combination of Methdilazine and Ethacrynic acid.	Essential hypertension [BA00]	[26]
Phenoxybenzamine	DM8KSQH	Moderate	Additive hypotensive effects by the combination of Methdilazine and Phenoxybenzamine.	Essential hypertension [BA00]	[16]
Nadolol	DMW6GVL	Moderate	Additive hypotensive effects by the combination of Methdilazine and Nadolol.	Essential hypertension [BA00]	[16]
Tolterodine	DMSHPW8	Moderate	Additive anticholinergic effects by the combination of Methdilazine and Tolterodine.	Functional bladder disorder [GC50]	[13]
Pilocarpine	DMV9ADG	Moderate	Antagonize the effect of Methdilazine when combined with Pilocarpine.	Glaucoma [9C61]	[19]
Carvedilol	DMHTEAO	Moderate	Additive hypotensive effects by the combination of Methdilazine and Carvedilol.	Heart failure [BD10-BD1Z]	[16]
Procarbazine	DMIK367	Moderate	Additive hypotensive effects by the combination of Methdilazine and Procarbazine.	Hodgkin lymphoma [2B30]	[21]
Isosorbide mononitrate	DMYLMU0	Moderate	Additive hypotensive effects by the combination of Methdilazine and Isosorbide mononitrate.	Hydrocephalus [8D64]	[16]
Cinacalcet	DMCX0K3	Moderate	Decreased metabolism of Methdilazine caused by Cinacalcet mediated inhibition of CYP450 enzyme.	Hyper-parathyroidism [5A51]	[22]
Acebutolol	DM0TI4U	Moderate	Additive hypotensive effects by the combination of Methdilazine and Acebutolol.	Hypertension [BA00-BA04]	[16]
Captopril	DM458UM	Moderate	Additive hypotensive effects by the combination of Methdilazine and Captopril.	Hypertension [BA00-BA04]	[16]
Methyldopa	DM5I621	Moderate	Additive hypotensive effects by the combination of Methdilazine and Methyldopa.	Hypertension [BA00-BA04]	[16]
Nebivolol	DM7F1PA	Moderate	Additive hypotensive effects by the combination of Methdilazine and Nebivolol.	Hypertension [BA00-BA04]	[16]
Levamlodipine	DM92S6N	Moderate	Additive hypotensive effects by the combination of Methdilazine and Levamlodipine.	Hypertension [BA00-BA04]	[16]
TAK-491	DMCF6SX	Moderate	Additive hypotensive effects by the combination of Methdilazine and TAK-491.	Hypertension [BA00-BA04]	[16]
Pindolol	DMD2NV7	Moderate	Additive hypotensive effects by the combination of Methdilazine and Pindolol.	Hypertension [BA00-BA04]	[16]
Diazoxide	DML1538	Moderate	Additive hypotensive effects by the combination of Methdilazine and Diazoxide.	Hypertension [BA00-BA04]	[16]
Felodipine	DMOSW35	Moderate	Additive hypotensive effects by the combination of Methdilazine and Felodipine.	Hypertension [BA00-BA04]	[16]
Irbesartan	DMTP1DC	Moderate	Additive hypotensive effects by the combination of Methdilazine and Irbesartan.	Hypertension [BA00-BA04]	[16]
Hydralazine	DMU8JGH	Moderate	Additive hypotensive effects by the combination of Methdilazine and Hydralazine.	Hypertension [BA00-BA04]	[16]
Hydrochlorothiazide	DMUSZHD	Moderate	Additive hypotensive effects by the combination of Methdilazine and Hydrochlorothiazide.	Hypertension [BA00-BA04]	[16]
Clevidipine butyrate	DMW4M97	Moderate	Additive hypotensive effects by the combination of Methdilazine and Clevidipine butyrate.	Hypertension [BA00-BA04]	[16]
Belladonna	DM2RBWK	Moderate	Additive anticholinergic effects by the combination of Methdilazine and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[13]
Amantadine	DMS3YE9	Moderate	Additive anticholinergic effects by the combination of Methdilazine and Amantadine.	Influenza [1E30-1E32]	[27]
ITI-007	DMUQ1DO	Moderate	Additive anticholinergic effects by the combination of Methdilazine and ITI-007.	Insomnia [7A00-7A0Z]	[13]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Methdilazine and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[28]
Physostigmine	DM2N0TO	Moderate	Antagonize the effect of Methdilazine when combined with Physostigmine.	Lips/oral mucosa miscellaneous disorder [DA02]	[15]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Methdilazine and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[29]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Methdilazine and Lasmiditan.	Migraine [8A80]	[30]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Methdilazine and Flibanserin.	Mood disorder [6A60-6E23]	[31]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Methdilazine and Thalidomide.	Multiple myeloma [2A83]	[32]
Ozanimod	DMT6AM2	Moderate	Additive hypotensive effects by the combination of Methdilazine and Ozanimod.	Multiple sclerosis [8A40]	[21]
Dextroamphetamine	DMMIHVP	Moderate	Antagonize the effect of Methdilazine when combined with Dextroamphetamine.	Narcolepsy [7A20]	[17]
Dimenhydrinate	DM264B3	Moderate	Additive anticholinergic effects by the combination of Methdilazine and Dimenhydrinate.	Nausea/vomiting [MD90]	[13]
Promethazine	DM6I5GR	Moderate	Additive anticholinergic effects by the combination of Methdilazine and Promethazine.	Nausea/vomiting [MD90]	[13]
Metoclopramide	DMFA5MY	Major	Additive antidopaminergic effects by the combination of Methdilazine and Metoclopramide.	Nausea/vomiting [MD90]	[33]
Bupropion	DM5PCS7	Major	Decreased metabolism of Methdilazine caused by Bupropion mediated inhibition of CYP450 enzyme.	Nicotine use disorder [6C4A]	[34]
Phendimetrazine	DM6TS1N	Moderate	Antagonize the effect of Methdilazine when combined with Phendimetrazine.	Obesity [5B80-5B81]	[17]
Amfepramone	DM9YSNQ	Moderate	Antagonize the effect of Methdilazine when combined with Amfepramone.	Obesity [5B80-5B81]	[17]
Lorcaserin	DMG6OYJ	Moderate	Increased risk of hyperprolactinemic effects by the combination of Methdilazine and Lorcaserin.	Obesity [5B80-5B81]	[35]
Polythiazide	DMCH80F	Moderate	Additive hypotensive effects by the combination of Methdilazine and Polythiazide.	Oedema [MG29]	[26]
Lofexidine	DM1WXA6	Moderate	Additive hypotensive effects by the combination of Methdilazine and Lofexidine.	Opioid use disorder [6C43]	[16]
Apraclonidine	DMO4PVE	Moderate	Additive CNS depression effects by the combination of Methdilazine and Apraclonidine.	Optic nerve disorder [9C40]	[36]
Flavoxate	DMKV4NL	Moderate	Additive anticholinergic effects by the combination of Methdilazine and Flavoxate.	Pain [MG30-MG3Z]	[13]
Methamphetamine	DMPM4SK	Moderate	Antagonize the effect of Methdilazine when combined with Methamphetamine.	Pain [MG30-MG3Z]	[37]
Safinamide	DM0YWJC	Moderate	Additive hypotensive effects by the combination of Methdilazine and Safinamide.	Parkinsonism [8A00]	[21]
Pergolide	DM14MAE	Moderate	Antagonize the effect of Methdilazine when combined with Pergolide.	Parkinsonism [8A00]	[38]
Opicapone	DM1BKA6	Moderate	Antagonize the effect of Methdilazine when combined with Opicapone.	Parkinsonism [8A00]	[39]
Rasagiline	DM3WKQ4	Moderate	Additive CNS depression effects by the combination of Methdilazine and Rasagiline.	Parkinsonism [8A00]	[21]
Levodopa	DMN3E57	Moderate	Antagonize the effect of Methdilazine when combined with Levodopa.	Parkinsonism [8A00]	[38]
Bromocriptine	DMVE3TK	Moderate	Antagonize the effect of Methdilazine when combined with Bromocriptine.	Parkinsonism [8A00]	[38]
Orphenadrine	DMW542E	Moderate	Additive anticholinergic effects by the combination of Methdilazine and Orphenadrine.	Parkinsonism [8A00]	[13]
Methylscopolamine	DM5VWOB	Moderate	Additive anticholinergic effects by the combination of Methdilazine and Methylscopolamine.	Peptic ulcer [DA61]	[13]
ABIRATERONE	DM8V75C	Moderate	Decreased metabolism of Methdilazine caused by ABIRATERONE mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[40]
Terazosin	DM3JCVS	Moderate	Additive hypotensive effects by the combination of Methdilazine and Terazosin.	Prostate hyperplasia [GA90]	[16]
Silodosin	DMJSBT6	Moderate	Additive hypotensive effects by the combination of Methdilazine and Silodosin.	Prostate hyperplasia [GA90]	[16]
Neupro	DMHEAB1	Moderate	Antagonize the effect of Methdilazine when combined with Neupro.	Restless legs syndrome [7A80]	[38]
Quetiapine	DM1N62C	Moderate	Additive anticholinergic effects by the combination of Methdilazine and Quetiapine.	Schizophrenia [6A20]	[13]
Mesoridazine	DM2ZGAN	Moderate	Additive anticholinergic effects by the combination of Methdilazine and Mesoridazine.	Schizophrenia [6A20]	[14]
Aripiprazole	DM3NUMH	Moderate	Additive anticholinergic effects by the combination of Methdilazine and Aripiprazole.	Schizophrenia [6A20]	[13]
Iloperidone	DM6AUFY	Moderate	Additive anticholinergic effects by the combination of Methdilazine and Iloperidone.	Schizophrenia [6A20]	[13]
Molindone	DMAH70G	Moderate	Additive anticholinergic effects by the combination of Methdilazine and Molindone.	Schizophrenia [6A20]	[13]
Thiothixene	DMDINC4	Moderate	Additive anticholinergic effects by the combination of Methdilazine and Thiothixene.	Schizophrenia [6A20]	[13]
Asenapine	DMSQZE2	Moderate	Additive anticholinergic effects by the combination of Methdilazine and Asenapine.	Schizophrenia [6A20]	[13]
Pimozide	DMW83TP	Moderate	Additive anticholinergic effects by the combination of Methdilazine and Pimozide.	Schizophrenia [6A20]	[13]
Papaverine	DMCA9QP	Moderate	Additive hypotensive effects by the combination of Methdilazine and Papaverine.	Tonus and reflex abnormality [MB47]	[16]
-----------


⏷ Show the Full List of 94 DDI Information of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7231).
2	Drug information of Methdilazine, 2008. eduDrugs.
3	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4	Effect of H1 blockers alone and in combination with morphine to produce antinociception in mice. Neuropharmacology. 1985 Jan;24(1):1-4.
5	Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. Mol Pharmacol. 2001 Mar;59(3):420-6.
6	Clinical research of Ibudilast on treating the steroid resistant allergic rhinitis. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2009 Jan;23(2):63-6.
7	Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79.
8	Update on prescription and over-the-counter histamine inverse agonists in rhinitis therapy. Curr Allergy Asthma Rep. 2009 Mar;9(2):140-8.
9	Central effects of cinnarizine: restricted use in aircrew. Aviat Space Environ Med. 2002 Jun;73(6):570-4.
10	Novel therapeutic usage of low-dose doxepin hydrochloride. Expert Opin Investig Drugs. 2007 Aug;16(8):1295-305.
11	Influence of epinastine hydrochloride, an H1-receptor antagonist, on the function of mite allergen-pulsed murine bone marrow-derived dendritic cell... Mediators Inflamm. 2009;2009:738038.
12	Examining the tolerability of the non-sedating antihistamine desloratadine: a prescription-event monitoring study in England. Drug Saf. 2009;32(2):169-79.
13	Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
14	Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
15	Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
16	Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
17	Achor MB, Extein I "Diet aids, mania, and affective illness" Am J Psychiatry 138 (1981): 392. [PMID: 7468847]
18	Bock JL, Nelson JC, Gray S, Jatlow PI "Desipramine hydroxylation: variability and effect of antipsychotic drugs." Clin Pharmacol Ther 33 (1983): 322-8. [PMID: 6130865]
19	Multum Information Services, Inc. Expert Review Panel.
20	Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
21	Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
22	Cerner Multum, Inc. "Australian Product Information.".
23	Burke RE, Fahn S, Mayeux R, Weinberg H, Louis K, Willner JH "Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease." Neurology 31 (1981): 1022-5. [PMID: 6115336]
24	Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
25	Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
26	Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
27	Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975): 212-5. [PMID: 123540]
28	Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
29	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
30	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
31	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
32	Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
33	Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985): 930-2. [PMID: 3929968]
34	Canadian Pharmacists Association.
35	Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):.
36	Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
37	Lake CR "Manic psychosis after coffee and phenylpropanolamine." Biol Psychiatry 30 (1991): 401-4. [PMID: 1912131]
38	Mims RB, Scott CL, Modebe O, Bethune JE "Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine." J Clin Endocrinol Metab 40 (1975): 256-9. [PMID: 1117978]
39	Product Information. Norprolac (quinagolide). Ferring Inc, North York, IA.
40	Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.